[HTML][HTML] The dark side of immunotherapy
N Okwundu, D Grossman, S Hu-Lieskovan… - Annals of …, 2021 - ncbi.nlm.nih.gov
Immunotherapy has broadened the therapeutic scope and response for many cancer
patients with drugs that are generally of higher efficacy and less toxicity than prior therapies …
patients with drugs that are generally of higher efficacy and less toxicity than prior therapies …
Hyperprogression under immune checkpoint-based immunotherapy—current understanding, the role of pd-1/pd-l1 tumour-intrinsic signalling, future directions and a …
M Kocikowski, K Dziubek, M Parys - Cancers, 2020 - mdpi.com
Immune evasion is a major challenge for the development of successful cancer treatments.
One of the known mechanisms is the expression of immune checkpoints (ICs)—proteins …
One of the known mechanisms is the expression of immune checkpoints (ICs)—proteins …
Hyperprogressive disease in patients with advanced renal cell carcinoma: a new pattern of post-treatment cancer behavior
Z Zheng, K Wu, Z Yao, X Mu, H Wu, W Zhao… - Immunologic …, 2020 - Springer
Renal cell carcinoma (RCC) is among the most common cancers of the genitourinary
system. Once RCC has progressed to a high tumor stage, surgery is no longer the optimal …
system. Once RCC has progressed to a high tumor stage, surgery is no longer the optimal …